Spero Therapeutics, Inc. Separate Account Liability Premium
Spero Therapeutics, Inc. (SPRO) reported Separate Account Liability Premium of $12.50 million for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-10.
Discontinued › Notes
us-gaap:SeparateAccountLiabilityPremium · last filed 2021-11-10
- Spero Therapeutics, Inc. separate account liability premium for the quarter ending 2021-09-30 was $0.00.
| Period end | Separate Account Liability Premium 3 month | Separate Account Liability Premium 6 month | Separate Account Liability Premium 9 month |
|---|---|---|---|
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $12.50M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $12.50M 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |